Penumbra Inc (NYSE:PEN) EVP Robert D. Evans sold 40,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $89.89, for a total value of $3,595,600.00. Following the sale, the executive vice president now directly owns 11,704 shares of the company’s stock, valued at $1,052,072.56. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Penumbra Inc (NYSE PEN) opened at $85.15 on Friday. The company has a market capitalization of $2,890.00 and a P/E ratio of 405.48. Penumbra Inc has a 1-year low of $65.20 and a 1-year high of $116.35.
Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, November 7th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.07. The business had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $79.17 million. Penumbra had a negative return on equity of 1.95% and a negative net margin of 2.19%. The company’s quarterly revenue was up 24.9% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. research analysts anticipate that Penumbra Inc will post -0.15 EPS for the current year.
A number of analysts have weighed in on the company. Canaccord Genuity increased their price objective on Penumbra from $100.00 to $113.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets increased their price objective on Penumbra from $96.00 to $117.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 8th. JPMorgan Chase & Co. cut Penumbra from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Zacks Investment Research raised Penumbra from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $111.50.
Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Penumbra by 1.2% in the 2nd quarter. FMR LLC now owns 5,042,974 shares of the company’s stock valued at $442,521,000 after buying an additional 57,801 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Penumbra by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,165,995 shares of the company’s stock valued at $190,066,000 after buying an additional 47,768 shares during the period. BlackRock Inc. lifted its holdings in shares of Penumbra by 4.7% in the 2nd quarter. BlackRock Inc. now owns 1,815,299 shares of the company’s stock valued at $159,294,000 after buying an additional 81,981 shares during the period. Lord Abbett & CO. LLC lifted its holdings in shares of Penumbra by 5.1% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,093,621 shares of the company’s stock valued at $95,965,000 after buying an additional 53,109 shares during the period. Finally, State Street Corp lifted its holdings in shares of Penumbra by 13.2% in the 2nd quarter. State Street Corp now owns 579,911 shares of the company’s stock valued at $50,887,000 after buying an additional 67,441 shares during the period. 71.71% of the stock is owned by institutional investors and hedge funds.
WARNING: This article was originally reported by Equities Focus and is owned by of Equities Focus. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.equitiesfocus.com/2018/01/07/penumbra-inc-pen-evp-robert-d-evans-sells-40000-shares.html.
Penumbra Company Profile
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.